“…Importantly, they spare the deactivating peptidolytic cleavage of PGP . However, only LYS006 and Acebilustat , have advanced to phase II clinical trials to date, albeit with limited efficacy . As a result, in the pursuit of enhanced inhibitor design, a deeper comprehension of the double hydrolysis mechanism of LTA4H remains imperative, particularly regarding the process of LTB4 formation.…”